BioPharma Dive 11. Feb. 2026 Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug
BioPharma Dive 10. Feb. 2026 Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study
BioPharma Dive 9. Feb. 2026 Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
BioPharma Dive 6. Feb. 2026 White House’s online service for drug sales debuts with limited impact on prices
BioPharma Dive 5. Feb. 2026 Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game